📰 Daniel Alkon News
Daniel Alkon News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Daniel Alkon. Real-time updates on events, politics, business and more.
December 6, 2023
/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
October 16, 2023
Patients with severe Alzheimer's Disease (AD) showed no cognitive decline throughout a ten-month trial while being treated with Bryostatin-1.
September 28, 2022
/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...
August 5, 2022
A minimally invasive skin test, which measures factors related to brain connections, shows high specificity and sensitivity in new research, with diagnoses of Alzheimer disease confirmed at autopsy.
July 26, 2022
/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...
July 20, 2022
/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...
June 22, 2022
This stifling of competing ideas, say a growing number of scholars, is a big reason why there is no treatment for Alzheimer’s.
May 17, 2022
/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...
April 20, 2022
/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...
April 19, 2022
/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...